## UCI <sup>1</sup> Chao Family Comprehensive Cancer Center

# Head and Neck Disease-Oriented Team

**Clinical Research Treatment Trial Flowchart** 

**Clinical Research Manager**: Mehir Tharani

Clinical Research Coordinators: Bao-An Huynh Natalie Arechiga Erin Palmer-Torrison Anastasiia Reipolska

www.cancer.uci.edu



## Neo-adjuvant or Adjuvant HNSCC

## 1<sup>st</sup> Line Recurrent/Metastatic HNSCC

UCI 23-106

#### **Recurrent/Metastatic Salivary Gland Cancer**

UCI 22-132

De-escalated Radiation for HPV 16+ Squamous Cell Carcinoma of the Oropharynx Coord: E. Palmer-Torrison Accrual: 17/111

## Pembro + Danyatirsen vs Pembro in 1<sup>st</sup> line Recurrent/Metastatic HNSCC Coord: N. Arechiga Accrual: 1/5

## UCI 23-228 TAK676 + Pembro 1<sup>st</sup> line Recurrent Metastatic HNSCC Coord: B. Huynh Accrual: 0/5

#### **ETCTN 10553**

Darolutamide + Leuprolide Acetate in Hormone Naïve AR+ Salivary Gland Cancer Coord: B. Huynh Accrual: 1/5

#### EA3202

2<sup>nd</sup>/3<sup>rd</sup> line Chemo +Cetuximab vs Chemo+Bev vs Atezo+Bev **Recurrent HNSCC** Coord: E. Torrison-Palmer Accrual: 2/5

#### Alliance A092105

2<sup>nd</sup> line Ipi/Nivo +/- Cabozantinib Recurrent NPC Coord: B. Huynh Accrual: 0/5

## HN009 Cisplatin Q3 weeks vs Weekly

Locally Advanced HNSCC Coord: E. Palmer-Torrison Accrual: 0/5

## UCI 23-190

Observation vs IP Adjuvant Coord: E. Palmer-Torrison Accrual: 0/5

#### UCI 21-173

Eval of Clinical & Radiological Benefit AHCC in Combo w/ SOC Tx for HPV+ Pts w/ HNSCC Coord: A. Reipolska Accrual: 0/34

UCI Chao Family Comprehensive Cancer Center

Trial Flowchart 2



## **Broad Phase 1 Trials**

## UCI 22-87 (RMC-6236)

Mechanism: TKI **Coordinator: Oliver** Ouines Accrual: 18/25

## UCI 21-40

(Locally Advanced or Metastatic Solid Tumors) DF6002 as a Monotherapy and in Combination w/ nivo Valerin CRC: B. Huynh Accrual: 5/10 Waitlist only

#### UCI 22-221 BiTe of B7-H6

(Central B7-H6 testing) **HCC and Pancreatic** (also NSCLC, HNSCC, CRC, and gastric)

> Coord: P. Yang Accrual: 3/12 Waitlist only

UCI 23-148 CJRB-01 (oral) + Pembrolizumab Mechanism: Live biotherapeutic product containing a novel strain belonging in the species Leuconostoc mesenteroides (L. mesenteroides + Pembrolizumab Coord: J. Choe Accrual: 0/6

UCI 23-197 DF6215 (IL-2) PI: Valerin CRC: N. Arechiga Accrual: 1/5 Waitlist only

